Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 07/15/2025 at 06:59, 9 months 25 days ago

Biophytis s’associe à Lynx Analytics dans le domaine de l’IA pour accélérer la découverte de médicaments contre la sarcopénie
Biophytis annonce un partenariat avec Lynx Analytics pour accélérer la découverte de médicaments contre la sarcopénie en utilisant l'IA. Objectif : identifier des molécules pour traiter la perte musculaire chez les personnes âgées

Biophytis IA Médicaments Sarcopénie Lynx Analytics
BRIEF

published on 07/11/2025 at 08:19, 9 months 29 days ago

Biophytis Reports 2024 Financial Results and Strategy for 2025

Drug Discovery Partnerships Biophytis Financials 2025 Strategic Plans Phase 2 And Phase 3 Trials
BRIEF

published on 07/11/2025 at 08:19, 9 months 29 days ago

Biophytis : Résultats 2024 et Perspectives 2025

Résultats Financiers Biophytis Partenariats Sarcopénie Obésité
PRESS RELEASE

published on 07/11/2025 at 08:16, 9 months 29 days ago

Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025
Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025 avec le lancement d'études de phase 2 dans l'obésité et de phase 3 dans la sarcopénie, renforcement de partenariats et de la plateforme de découverte de médicaments

Biophytis Partenariats Résultats 2024 Études Cliniques Perspectives 2025
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 9 months 29 days ago

Biophytis Reports 2024 Financial Results and 2025 Outlook
Biophytis announces 2024 financial results, 2025 outlook. Initiates Phase 2 study in obesity, Phase 3 study in sarcopenia. Strengthens drug discovery platform. Resumes trading on Euronext Growth Paris

Financial Results Biophytis Drug Discovery Phase 3 Phase 2
REGULATED PRESS RELEASE

published on 07/11/2025 at 08:14, 9 months 29 days ago

Biophytis dévoile ses résultats 2024 et ses perspectives pour 2025
Biophytis révèle ses résultats 2024 et perspectives 2025 avec lancement d'études cliniques et renforcement de sa plateforme technologique de découverte de médicaments. Communiqué de presse publié par Biophytis SA

Biophytis Résultats 2024 Études Cliniques Découverte De Médicaments Perspectives 2025
BRIEF

published on 07/08/2025 at 07:05, 10 months 1 day ago

Biophytis présente à la Conférence mondiale sur le vieillissement et le rajeunissement 2025

Innovation Biophytis Longévité Sarcopénie ARC 2025
BRIEF

published on 07/08/2025 at 07:05, 10 months 1 day ago

Biophytis Highlights Longevity Innovation at ARC 2025

Innovation Biophytis Longevity Sarcopenia ARC 2025
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 10 months 1 day ago

Biophytis au cœur de l’innovation dans la longévité à la conference World Aging & Rejuvenation 2025
Biophytis participe à la 7e conférence mondiale sur le vieillissement et le rajeunissement pour présenter ses résultats sur la sarcopénie et le candidat-médicament BIO101

Biophytis Conference Longévité BIO101 SARA Program
REGULATED PRESS RELEASE

published on 07/08/2025 at 07:00, 10 months 1 day ago

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025
Biophytis SA announces participation in ARC 2025 to present results of BIO101 in sarcopenia at the World Aging & Rejuvenation Conference, aiming to strengthen scientific visibility and expand in the longevity market

Sarcopenia Biophytis SA BIO101 Longevity Market ARC 2025

Published on 05/09/2026 at 01:55, 7 hours 42 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 7 hours 57 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 8 hours 7 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 9 hours 37 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 10 hours 36 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

Published on 05/08/2026 at 20:38, 12 hours 59 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 14 hours 24 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 14 hours 35 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 15 hours 8 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 15 hours 8 minutes ago

Designated Person Notification

View all EQS

Published on 05/07/2026 at 19:15, 1 day 14 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 14 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 14 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 14 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 14 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

News